Table 3.
Univariate analysis of overall survival after diagnosis of sPAP in MDS
| Variable at diagnosis of sPAP | (n) | 75% of OS (months) | 50% of OS (months) | HR (95% CI) | P value |
|---|---|---|---|---|---|
| Age: 51 yrs or younger |
16 |
8 |
16 |
|
|
| Older than 52 yrs |
15 |
10 |
15 |
1.29 (0.48-3.41) |
0.607 |
| Gender: Male |
19 |
10 |
16 |
|
|
| Female |
12 |
11 |
21 |
1.12 (0.43-2.94) |
0.804 |
| MDS group: mild |
13 |
10 |
15 |
|
|
| severe |
18 |
11 |
16 |
1.11 (0.42-2.95) |
0.830 |
| Symptoms: (-) |
5 |
26 |
26 |
|
|
| (+) |
26 |
6 |
15 |
1.50 (0.33-6.65) |
0.592 |
| Dx procedure: Bronchoscopy |
23 |
11 |
13 |
|
|
| Surgical biopsy |
8 |
15 |
26 |
0.69 (0.23-2.04) |
0.507 |
| Respiratory failure: (-) |
21 |
11 |
26 |
|
|
| (+) |
10 |
5 |
10 |
2.18 (0.77-6.22) |
0.142 |
| Use of corticosteroid: (-) |
16 |
16 |
80 |
|
|
| (+) |
15 |
10 |
13 |
3.20 (1.09-9.38) |
0.034 |
| Serum KL-6 (U/ml): < 1960 |
16 |
13 |
26 |
|
|
| 1960 ≦ |
15 |
5 |
15 |
1.52 (0.58-4.00) |
0.389 |
| Serum SP-D (ng/ml): < 147 |
15 |
10 |
26 |
|
|
| 147 ≦ |
15 |
8 |
15 |
1.80 (0.62-5.22) |
0.278 |
| Serum SP-A (ng/ml): < 79 |
16 |
11 |
26 |
|
|
| 79 ≦ |
14 |
5 |
15 |
2.79 (0.965-8.06) |
0.058 |
| %VC: 87 ≦ |
11 |
15 |
34 |
|
|
| < 87 |
11 |
8 |
15 |
3.27 (0.79-13.52) |
0.101 |
| FEV1%: 86 ≦ |
12 |
8 |
16 |
|
|
| < 86 |
10 |
13 |
34 |
0.52 (0.14-1.87) |
0.322 |
| %DLco: 44 ≦ |
9 |
21 |
34 |
|
|
| < 44 | 8 | 5 | 13 | 9.98 (1.03-96.11) | 0.046 |
CI indicates confidence interval; OS, overall survival; DLco, diffusing capacity of the lung for carbon monoxide; Dx, diagnosis; FEV, forced expiratory volume; HR, hazard ratio; KL-6, krebs von den lungen-6; MDS, myelodysplastic syndrome; SP-A, surfactant protein -A; sPAP, secondary pulmonary alveolar proteinosis; SP-D, surfactant protein -D; VC, vital capacity.